A Phase 1 Study of KTX-1001 in People With Multiple Myeloma

Full Title

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma

Purpose

Multiple myeloma that keeps growing after treatment can cause cancer cells to build up inside the bones. The cancer cells crowd out healthy blood cells and make abnormal proteins that cause discomfort. Researchers in this study want to find the best dose of KTX-1001 to treat multiple myeloma that grows after treatment.

KTX-1001 attacks the cells that make these abnormal proteins. It targets the activity of a mutated (changed) or overexpressed (too much is made) gene called MMSET. This gene helps turn healthy blood cells into cancer cells. KTX-1001 is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.